X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL

X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL

Abstract Acute lymphoblastic leukemia (ALL) represents the most frequent malignancy in children, and relapse/refractory (r/r) disease is difficult to treat, both in children and adults. In search for novel treatment options against r/r ALL, we studied inhibitor of apoptosis proteins (IAP) and Smac m...

Повний опис

Бібліографічні деталі
Автори: Michela Carlet, Karin Schmelz, Jenny Vergalli, Tobias Herold, Daniela Senft, Vindi Jurinovic, Thomas Hoffmann, Jutta Proba, Nina Weichert, Christian Junghanß, Mareike Roth, Georg Eschenburg, Malwine Barz, Günter Henze, Cornelia Eckert, Angelika Eggert, Johannes Zuber, Patrick Hundsdoerfer, Irmela Jeremias
Формат: Стаття
Мова:English
Опубліковано: Springer Nature 2023-01-01
Серія:EMBO Molecular Medicine
Предмети:
PDX
relapsed/refractory acute lymphoblastic leukemia
smac mimetics
therapeutic target
XIAP
Онлайн доступ:https://doi.org/10.15252/emmm.202114557

Інтернет

https://doi.org/10.15252/emmm.202114557

Схожі ресурси